CliniCAP
ActiveCliniCAP has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €148k and a net result of €141k. Equity is growing by ~44.7% per year across the filed fiscal years. Its solvency ranks better than 42% of 16527 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Checked score
Score 2025
88
/ 100
Excellent
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability100=
Solvency79▼-12
Growth78=
Track record94
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €13k at 30 days acceptable
Liquidity ample (current ratio 2.18 against 3.6 in 2024; short-term debt: 40.2% and cash: 77.1% of total assets), and 46.2% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 86
Relative position
BE, all sectors
reference
Sector 86
lower
← fewer bankruptcies
more bankruptcies →
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
53.8%
Return on assets
51.1%
Age of the figures
9 mo
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 4 filingsDeviation from the deadline
2025
31 d late
2024
29 d late
2023
29 d late
2022
31 d late
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
21-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€148k▼ 5.4%
2024 · €156k
2022: €14k
2023: €64k
2024: €156k
2022 → 2025
Total assets
€275k▲ 16.6%
2024 · €236k
2022: €17k
2023: €128k
2024: €236k
2022 → 2025
Net result
€141k▲ 50.0%
2024 · €94k
2022: €6k
2023: €50k
2024: €94k
2022 → 2025
Working capital
€130k▼ 4.1%
2024 · €136k
2022: €14k
2023: €41k
2024: €136k
2022 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line2022202320242025Trend
Equity€14k-€64k▲ 359%€156k▲ 146%€148k▼ 5.4%
Operating result€8k-€64k▲ 705%€122k▲ 90.1%€167k▲ 36.8%
Net result€6k-€50k▲ 682%€94k▲ 88.1%€141k▲ 50.0%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result has risen three years in a row; 2025 is 37% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €275k
Fixed assets
€34k▼ 28.7%
Current assets
€241k▲ 28.2%
Equity and liabilities €275k
Equity
€148k▼ 5.4%
Debt
€127k▲ 59.9%
The debt ratio rises from 33.7% to 46.2%. Equity is lower and debt is higher.
Key figures and ratios
EBITDA
€181k▲
2024 · €136k
Cash flow
€154k▲
2024 · €107k
Solvency
53.8%▼
2024 · 66.3%
Current ratio
2.18▼
2024 · 3.60
Quick ratio
2.18▼
2024 · 3.60
Debt / equity
0.86▲
2024 · 0.51
ROE
94.9%▲
2024 · 59.9%
ROA
51.1%▲
2024 · 39.7%
Interest coverage
114.00▲
2024 · 67.63
Debt
€127k▲
2024 · €79k
Debt ≤ 1 year
€111k▲
2024 · €52k
Debt > 1 year
€16k▼
2024 · €27k
Income taxes
€25k▼
2024 · €26k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€236k€275k▲
Fixed assets21/28€48k€34k▼
Tangible fixed assets22/27€48k€34k▼
Plant, machinery and equipment23€3k€3k▼
Furniture and vehicles24€45k€32k▼
Current assets29/58€188k€241k▲
Amounts receivable within one year40/41€3k€28k▲
Trade receivables40€3k€3k=
Other amounts receivable41€0€25k▲
Cash at bank and in hand54/58€185k€212k▲
Deferred charges and accrued income490/1-€591
Equity and liabilities
Total equity and liabilities10/49€236k€275k▲
Equity10/15€156k€148k▼
Contributions10/11€8k€8k=
Profit (loss) carried forward14€149k€141k▼
Amounts payable17/49€79k€127k▲
Amounts payable after more than one year17€27k€16k▼
Financial debts170/4€27k€16k▼
Amounts payable within one year42/48€52k€111k▲
Current portion of amounts payable after more than one year42€10k€11k▲
Trade debts44€87-
Suppliers440/4€87-
Taxes, remuneration and social security45€42k€28k▼
Taxes450/3€42k€28k▼
Other amounts payable47/48-€71k
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€14k€14k▲
Other operating charges640/8€618€432▼
Gross operating margin9900€136k€181k▲
Operating profit (loss)9901€122k€167k▲
Financial charges65/66B€2k€2k▼
Recurring financial charges65€2k€2k▼
Profit (loss) for the period before taxes9903€120k€165k▲
Income taxes67/77€26k€25k▼
Profit (loss) for the period9904€94k€141k▲
Profit (loss) for the period to be appropriated9905€94k€141k▲
Appropriation of the result
Profit (loss) to be appropriated9906€150k€290k▲
Profit (loss) brought forward from the previous period14P€56k€149k▲
Profit to be distributed694/7€1k€149k▲
Return on contributions (dividend)694€1k€149k▲
The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
31-08
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema · 31 days late
2025
31-12
Financial
Highest result since 2022net €141k ▲50%
Operating result €167k, net result €141k, both a record.
29-08
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 29 days late
2024
31-12
Financial
Equity above €150kEq €156k ▲146%
3 profitable years in a row build equity to €156k.
29-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 29 days late
2023
31-08
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 31 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Herzele · 3 establishment units since 2022
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Kriekelaar 3a9550 HerzeleGround area
9.1 ha
Building footprint
5,169 m²
Volume, LiDAR
4,346 m³
3 parcels, Flanders · tallest building 6.8 m, ±2 floors. Linked by address, not a title deed.
3 establishment units
CliniCAP
since 20222.336.714.558
CliniCAP
since 20222.336.714.657
CliniCAP
since 20222.336.714.756
3 parcels
Flanders
3
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 41302C1191/00S000 | Flanders | 8.0 ha | 1 · 1,006 m² | 6.5 m · 1 fl. |
| 45035B0038/00S002 | Flanders | 1.0 ha | 1 · 3,962 m² | - |
| 41067B0898/00F000 | Flanders | 767 m² | 1 · 201 m² | 6.8 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 2
3 of 3 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
1 of these parcels carry protected heritage (source: regional heritage registers, Onroerend Erfgoed / patrimoine.brussels).
Similar companies · same sector, comparable size
DR. E. SCHREURS
BE 0459.653.108
Tremelo · Eq €148k
PROF.DR.BEULS
BE 0891.733.272
Hasselt · Eq €149k
Dr. Tim Decraecke, huisarts
BE 0665.553.028
Zwalm · Eq €149k
VDSlab
BE 0686.836.808
Les Bons Villers · Eq €151k
LC LAB
BE 0698.703.470
La Louvière · Eq €145k
Of 698 companies in sector 86910 we hold annual accounts for 520. 383 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded16-09-2022
Fiscal year end31-12
Activities, NACEBEL
86901Human health activities
86910Medical imaging and medical laboratories
72109Other research and development on natural sciences
Sources
Crossroads Bank for EnterprisesNational Bank · 4 filingsAddress and cadastre registers
Data from official sources, last processed on 20-09-2026. Scores and ratios are computed by Checked and are not a credit decision.